Bionano Genomics

What Bionano Genomics does

Bionano Genomics, Inc. (NASDAQ: BNGO) is a Delaware-incorporated biotechnology company founded in 2003 and headquartered in San Diego, California, that develops optical genome mapping (OGM) solutions for research and clinical customers. Its core technology images fluorescently labeled ultra-high molecular weight DNA to detect all classes of structural variants across the genome at a resolution that traditional karyotyping, FISH, chromosomal microarrays, and short-read NGS cannot match. The commercial platform comprises two instrument families (the next-generation Stratys and the legacy Saphyr), a sample preparation workflow anchored by the Ionic isotachophoresis-based purification system acquired from Purigen Biosystems in 2022, and a software stack led by VIA (multi-modal variant interpretation) and Access (data management).

The company monetizes the platform through a razor-and-blade model: high-value capital instrument sales (Stratys/Saphyr) generate the initial transaction, while flow cells, sample preparation kits, Ionic purification kits, and VIA/Access software subscriptions produce recurring consumables and software revenue (Q1 2026 consumables were $3.9M, up 20% YoY, on 8,178 flow cells). A managed-services layer — Bionano Laboratories (CLIA-certified), EnFocus Analysis, and a Certified Service Provider network — serves customers that prefer outsourced OGM rather than in-house instrumentation. Reimbursement infrastructure (Category I CPT codes for constitutional genetic disorders and hematologic malignancies, the latter with a 47% CMS payment increase effective January 1, 2026, and an FDA-cleared OGM Dx Postnatal Whole Genome SV Test) anchors the move from research-use to clinical diagnostic use cases. GTM is enterprise field sales to clinical cytogenetics labs, cancer centers, and translational research institutions, supported by a 500+ publication evidence base, conference presence (ASHG, ACMG, AMP, ESHG), and distribution partners in international markets including China (via Diagens). FY2025 revenue was $28.5M with a 46% gross margin, and Q1 2026 revenue of $6.7M marked the first YoY growth quarter after a 7% revenue decline in 2025.

Name

Bionano Genomics

Legal name

Bionano Genomics, Inc.

Website

https://bionanogenomics.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

Bionano Genomics (NASDAQ: BNGO) sells optical genome mapping instruments, consumables, and software that detect structural variants in DNA for clinical cytogenetics labs, cancer centers, and translational research institutions, generating revenue through instrument sales and recurring flow cell, reagent, and software subscriptions.

Ownership category

akta.pro rank

Product category

Genomic Mapping Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Software Publishers (5132)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Optical genome mapping
• Structural variant detection
• Cytogenomics instruments
• Genome analysis platforms
• Nucleic acid purification

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Instrument Systems: Sale of OGM capital equipment including Stratys and Saphyr systems. These are high-value instruments representing significant one-time capital purchases by laboratories.
2. Consumables (Flow Cells): Recurring consumable revenue from flow cells and sample preparation kits used with OGM systems. Q1 2026 consumables revenue was $3.9 million, representing 20% growth. 8,178 flow cells sold in Q1 2026.
3. Software (VIA, Access): Software licenses for data analysis including VIA software and Access platform. Software revenue provides recurring subscription-like revenue.
4. Data Services: OGM data services offered through Bionano Laboratories and Certified Service Providers for customers who prefer outsourced analysis.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Bionano Genomics sells optical genome mapping (OGM) instrument systems (Stratys and Saphyr), nucleic acid purification instruments (Ionic) and kits, proprietary analysis software (VIA, Access, EnFocus), and OGM data services to clinical cytogenetics laboratories, cancer centers, and genetic disease research institutions. The technology detects structural variants across the entire genome that traditional cytogenetics and next-generation sequencing miss.

Product overview

Bionano Genomics offers a comprehensive optical genome mapping (OGM) platform consisting of two main instrument systems (Stratys™ and Saphyr®), supported by VIA™ and Access™ software for data analysis and interpretation. The portfolio includes sample preparation and purification consumables (Ionic® purification kits), compute infrastructure solutions, and laboratory services. The Stratys System is the next-generation flagship OGM instrument, while the Saphyr System serves as the established system. The Ionic System provides nucleic acid purification using isotachophoresis technology. All products are designed for research use only, with the OGM Dx Postnatal Whole Genome SV Test representing the company's entry into clinical diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• Stratys: OGM Mapping System providing digital precision in detecting structural variants
• Saphyr
• VIA
• Ionic

Products and services

• Stratys System Next-generation optical genome mapping (OGM) system that provides high-throughput detection and analysis of all classes of structural variants with enhanced sensitivity and faster turnaround time, designed for clinical and research laboratories.
• Saphyr System Optical genome mapping system that provides genome-wide detection and analysis of all classes of structural variants from ultra-high molecular weight DNA using OGM technology, targeted at clinical cytogenetics and research laboratories.
• VIA Software Analysis software that receives and interprets data from optical genome mapping (OGM), next-generation sequencing (NGS), and microarrays to contextualize all classes of genomic variation for comprehensive interpretation by clinical and research users.
• Access Software Software platform for data access and management of optical genome mapping results and workflows, designed for laboratory data management and analysis.
• Ionic System Nucleic acid purification system that uses isotachophoresis (ITP) technology to isolate, purify, and concentrate genomic DNA and RNA from cells, tissue, and FFPE samples with minimal hands-on time for research and clinical laboratories.
• Ionic Purification Kits Reagent kits for use with the Ionic System, providing G2 chemistry for DNA and RNA purification workflows, sold as recurring consumables to laboratories using the Ionic platform.
• Sample Preparation Kits Kits for preparing ultra-high molecular weight DNA samples for optical genome mapping analysis on Saphyr and Stratys systems, sold as recurring consumables.
• EnFocus Analysis Fast turnaround analysis service providing focused results for specific applications using optical genome mapping technology, offered to customers seeking targeted insights without operating in-house instruments.
• Compute Solutions Hardware and infrastructure solutions for processing and analyzing optical genome mapping data, supporting customer computational workflows for OGM analysis.
• OGM Data Services Laboratory services offering optical genome mapping analysis for customers who prefer outsourced testing rather than operating in-house instruments, delivered through Bionano Laboratories and Certified Service Providers.
• Bionano Laboratories CLIA-certified laboratory providing optical genome mapping testing services for clinical and research applications, enabling customers to access OGM without purchasing instruments.

Quantifiable outcome

• 97.8% detection rate in T-ALL cases compared to 55% for conventional cytogenetic methods
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• RevvitycoreGTM or Marketing Partner · 20 June 2024Software marketing agreement for newborn sequencing research. Revvity, a leader in health sciences, markets Bionano's software solutions for newborn screening and sequencing research applications.
• Diagens BiotechnologycoreStrategic or Co-development Partner · 17 April 2024Partnership to commercialize the first ever clinical cytogenetic analysis that combines OGM and Artificial Intelligence. Diagens, a Chinese medical imaging AI company specializing in chromosome analysis, holds 30.6% share of China's chromosome karyotype analysis market. The partnership aims to leverage AI capabilities with OGM for enhanced cytogenetic analysis.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pacific Biosciences: PacBio provides long-read sequencing instruments (HiFi sequencing) that increasingly compete with OGM in structural variant detection. Both companies sell high-value capital instruments and consumables to clinical and research genomics laboratories.
• Oxford Nanopore Technologies: Oxford Nanopore offers long-read sequencing platforms capable of detecting structural variants across the genome. It directly overlaps with OGM in addressing SV detection limitations of short-read NGS and traditional cytogenetics.
• 10x Genomics: 10x Genomics sells linked-read and single-cell genomic analysis platforms that, like OGM, aim to resolve structural variants and complex genomic architecture beyond standard short-read sequencing. It targets the same translational and clinical research customers.

Broad incumbents

• Illumina: Illumina is the dominant short-read sequencing provider and a broad incumbent in genomics instruments and software. Its installed base of sequencers and roadmap improvements (e.g., longer reads, new chemistry) represent the primary competitive backdrop for OGM.
• Thermo Fisher Scientific: Thermo Fisher provides a broad portfolio of life sciences instruments, including cytogenetic and molecular diagnostic systems that compete for the same clinical laboratory budgets as Bionano's OGM platforms.
• Revvity: Revvity (formerly PerkinElmer Life Sciences) provides genomics instruments, reagents, and newborn screening solutions. It is a current Bionano GTM partner for newborn sequencing software but also a broad incumbent competing for lab budgets.
• QIAGEN: QIAGEN provides sample preparation, molecular diagnostics, and bioinformatics solutions used by the same clinical and research labs Bionano targets. Its consumables and digital PCR/PCR franchises overlap with the lab workflow Bionano serves.
• Agilent Technologies: Agilent supplies analytical laboratory instruments, microarrays, and genomics software (including CytoGenomics for cytogenetics). It competes in the cytogenomics workflow where Bionano VIA software and OGM systems are positioned.

Emerging players

• Nabsys: Nabsys is developing electronic genome mapping for high-resolution structural variant detection. It is an emerging player pursuing a similar problem space to OGM but using a different detection modality, making it a direct emerging competitor in SV analysis.
• MGI Tech (BGI Group): MGI Tech produces sequencers (DNBSEQ) and automation for genomics labs at competitive price points and is expanding globally. It represents an emerging threat in genomic analysis instruments, particularly in international markets where Bionano is also growing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bionanogenomics
• LinkedInlinkedin.com/company/bionano-genomics-inc-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds20 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionano Genomics